Author of

• 20171

  +

  P2.07 - Immunology and Immunotherapy (ID 708)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23414

    +

    P2.07-039 - Nivolumab Experience in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC) in Toledo, Spain (ID 9568)

    09:30 - 09:30  |  Author(s): B. Trujillo Alba
    • Abstract

    Background:
    Nivolumab is a fully human IgG4 programmed death-1 (PD-1), an immune checkpoint inhibitor antibody and it has demonstrated durable responses and tolerability in heavily pretreated patients with advanced NSCLC. This is an observational study to describe our experience with Nivolumab in previously treated patients with advanced NSCLC .
    
    Method:
    The aim of the study was to report the efficacy and safety profile of Nivolumab in pretreated patients with advanced NSCLC of our everyday clinical practice. The exploratory assessments include the progression-free survival (PFS) and overall survival (OS) and the rates of treatment related adverse events (AEs). Elegibility criteria included, histologically or citologically confirmed NSCLC clinical stage IIIB vs IV, evaluable disease, at least one prior therapy from January of 2016 to current date.
    
    Result:
    From January of 2016 to May of 2017 , a total of 46 patients were enrolled in the study from our Hospital. The patients demographics were: median age 64 years (47-77), 6 (14%) female and 38 (86%) male. El 61% (n=27) non squamous-cell and 39% (n=17) squamous-cell carcinoma. The stage was IV in 71%(n=53) and III in 29% (n=13) .All the stage III patients have been treated with concurrent chemoradiotherapy. 41 patients ( 93%) have received platinum-based therapy previously to Nivolumab : 22 ( 50%) combined with Premetrexed and 19 (43%) with other drugs. 72% (n=20) have been treated with 2 or more prior therapy lines. Among 48 patients evaluated the best response to Nivolumab was: 4% (n=2) complete response, 36%(n=34)partial response and 25%(n=11) disease stabilization At the time of database lock, the median of PFS with Nivolumab was 2.3 IC 95% (1.2-2.7) and OS was not reached. Grade 1-2 treatment related adverse events (AEs) occurred in 32% patients and the most common ones were endocrine 16% (n=7) and neumonitis 4% ( n=2) but there were one case isolated of grade 3-4 encephalitis, nephritis and hypophysitis. The 4% ( n=29) patients need to be admitted to the hospital due Nivolumab toxicity versus 16% due to chemotherapy toxicity.
    
    Conclusion:
    Early data from this study suggest that Nivolumab is effective and well tolerated in patients with pretreated advanced NSCLC but in our serie the toxicity was relevant with some patients